AL
ALSAF.PA Safe Orthopaedics SA
- Market cap
- EUR 128K
- P/E
- -
- P/B
- 0.40x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALSAF.PA undervalued?
Graham numberThe Graham number of Safe Orthopaedics SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Safe Orthopaedics SA fundamental analysis
3 of 11 checks passedROE 0/2
Negative ROE (-2325%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-57.14%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 0/2
The company has a high debt to equity ratio (2237%), which means it owes a lot of money compared to what it actually owns, making it financially risky.
Revenue Growth 0/2
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.
Net Profit Growth 0/2
This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.
Assets Growth 1/2
With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity
Graham Number 1/1
The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.
Dividend Growth 0/2
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.
Dividend 0/2
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.
Buffet Intrinsic Value 0/1
The company's stock presents a potential concern as it appears overvalued (-16) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Safe Orthopaedics SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Safe Orthopaedics SA
Safe Orthopaedics SA, a medical technology company, develops and markets ready-to-use sterile implants and instrumentation for spinal surgery in France. It provides SteriSpine PS, for posture vixation; SteriSpine VA, a vertebral fracture solution; and SteriSpine CC/LC, an interbody fusion solution, including Walnut, Cedar, and Elm interbody cages. The company was founded in 2010 and is headquartered in Fleurieux-sur-l'Arbresle, France.
Full company profileSafe Orthopaedics SA financial statements
Safe Orthopaedics SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.37K | 3.11K | 3.47K | 4.70M | 3.66M | 4.55M | 5.86M | 5.81M | 5.04M | 5.40M |
| Gross Profit | 786.00 | 1.38K | 1.51K | -3.83M | -5.05M | -5.74M | -4.36M | 4.32M | -6.04M | 3.62M |
| Operating Income | -6.29M | -5.43M | -6.15M | -7.46M | -6.67M | -7.58M | -5.96M | -7.98M | -2.25M | -3.50M |
| EBITDA | -5.49M | -6.14M | -5.85M | -6.37M | -6.88M | -5.20M | -5.62M | -267M | -7.11M | -3.00M |
| Net Income | -6.01M | -6.58M | -5.80M | -7.97M | -8.31M | -6.71M | -6.97M | -205M | -1.93B | -4.10M |
| EPS | - | - | - | - | -207,650,000 | -54,992 | -57,090 | -2,361,425 | -241,165 | -23 |
| Balance Sheet | ||||||||||
| Total Assets | 8.00M | 8.06M | 8.57M | 5.64M | 14.3M | 14.9M | 16.5M | 77.9M | 11.0M | 11.8M |
| Total Liabilities | 7.64M | 7.00M | 7.38M | 9.92M | 14.1M | 14.5M | 17.8M | 280M | 19.5M | 22.5M |
| Shareholders' Equity | 367K | 1.06M | 1.19M | -4.28M | 237K | 398K | -1.28M | -202M | -8.42M | -10.7M |
| Cash & Short-term Investments | 3.66M | 3.74M | 3.16M | 125K | 2.44M | 913K | 303K | 780K | 317K | 390K |
| Total Debt | 6.01M | 5.18M | 4.91M | 6.61M | 9.14M | 8.86M | 9.89M | 271M | 11.8M | 13.5M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.80M | -4.93M | -6.22M | -5.04M | -5.99M | -6.26M | -5.47M | -1.14M | -3.27M | -2.01M |
| Capital Expenditure | 143.00 | 88.00 | 124.00 | 451K | 548K | 1.96M | 858K | 56.0K | 5.00K | 140K |
| Free Cash Flow | -5.94K | -5.02K | -6.34K | -5.49M | -7.30M | -8.81M | -6.33M | -1.19M | -3.27M | -2.15M |
| Ratios | ||||||||||
| ROE | -1,636.2% | -622.0% | -485.8% | - | -3,504.6% | -1,685.7% | - | - | - | - |
| ROA | -75.0% | -81.6% | -67.7% | -141.3% | -57.9% | -45.1% | -42.2% | -263.6% | -17,486.8% | -34.7% |
| Net Profit Margin | -253,911.2% | -211,414.8% | -167,098.8% | -169.6% | -227.1% | -147.3% | -118.8% | -3,536.0% | -38,272.6% | -75.9% |
| Debt to Equity | 16.37x | 4.90x | 4.11x | - | 38.56x | 22.26x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Safe Orthopaedics SA dividends
Safe Orthopaedics SA has not paid dividends in the last 10 fiscal years.
Last stock split: 1:1000 on Jul 7, 2025.
Who owns Safe Orthopaedics SA
Ownership data of Safe Orthopaedics SA is not available yet.
Safe Orthopaedics SA company profile
- Company name
- Safe Orthopaedics SA
- Ticker
- ALSAF.PA
- ISIN
- FR001400ZU25
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 77
- Fiscal year end
- December
- Address
- 80 rue Montepy, Fleurieux-sur-l'Arbresle, France, 69210
- Phone
- 33 4 81 09 87 01
- Website
- safeorthopaedics.com
About Safe Orthopaedics SA
Safe Orthopaedics SA, a medical technology company, develops and markets ready-to-use sterile implants and instrumentation for spinal surgery in France. It provides SteriSpine PS, for posture vixation; SteriSpine VA, a vertebral fracture solution; and SteriSpine CC/LC, an interbody fusion solution, including Walnut, Cedar, and Elm interbody cages. The company was founded in 2010 and is headquartered in Fleurieux-sur-l'Arbresle, France.
Safe Orthopaedics SA management
4- Mr. Nicolas PapillonChief Executive Officer
- Mr. Philippe LauritoCEO & Director · born 1969
- Mr. Thomas DrouloutCo-Founder & CTO · born 1976
- Mr. Rodolphe CadioAdministrative & Financial Director & Director · born 1977